公开(公告)号：US20110112099A1

公开(公告)日：2011-05-12

申请号：US12674230

申请日：2008-08-21

Applicant: Takayuki Nakashima ,  Yukimasa Shiotsu

Inventor： Takayuki Nakashima ,  Yukimasa Shiotsu

IPC: A61K31/535 ,  A61K31/4965 ,  A61K31/47 ,  A61K31/445 ,  A61K31/12 ,  A61P35/00 ,  A61P35/02

CPC classification number: C07D295/185 ,  A61K31/047 ,  A61K31/12 ,  A61K31/165 ,  A61K31/216 ,  A61K31/4402 ,  A61K31/4406 ,  A61K31/445 ,  A61K31/472 ,  A61K31/495 ,  A61K31/5375 ,  A61K45/06 ,  C07C49/84 ,  C07C69/732 ,  C07C205/45 ,  C07D211/42 ,  C07D211/52 ,  C07D211/62 ,  C07D213/30 ,  C07D217/06 ,  C07D295/088 ,  A61K2300/00

Abstract: The present invention provides therapeutic agents for a cancer resistant to a protease inhibitor which comprises, as an active ingredient, a benzoyl compound represented by formula (I): [wherein n represents an integer of 1 to 5; R1 represents substituted or unsubstituted lower alkyl, CONR7R8 (wherein R7 and R8, which may be the same or different, each represent a hydrogen atom, substituted or unsubstituted lower alkyl, or the like), or the like; R2 represents substituted or unsubstituted aryl or the like; R3 and R5, which may be the same or different, each represent a hydrogen atom, substituted or unsubstituted lower alkyl, or the like; R4 represents a hydrogen atom or the like; and R6 represents a hydrogen atom, halogen, substituted or unsubstituted lower alkyl, or the like] or a pharmaceutically acceptable salt thereof as a heat shock protein 90 (Hsp90) family protein inhibitor, and the like.

Abstract translation: 本发明提供了对蛋白酶抑制剂有抗性的癌症治疗剂，其包含作为活性成分的式（I）表示的苯甲酰基化合物：[其中n表示1〜5的整数， R1表示取代或未取代的低级烷基CONR7R8（其中R7和R8可相同或不同，各自表示氢原子，取代或未取代的低级烷基等）等; R2表示取代或未取代的芳基等; R 3和R 5可以相同或不同，各自表示氢原子，取代或未取代的低级烷基等; R4表示氢原子等; R6表示氢原子，卤素，取代或未取代的低级烷基等]或其药学上可接受的盐作为热休克蛋白90（Hsp90）家族蛋白抑制剂等。

公开(公告)号：US20090247522A1

公开(公告)日：2009-10-01

申请号：US12427847

申请日：2009-04-22

Applicant: Shinji Nara ,  Hiroshi Nakagawa ,  Yutaka Kanda ,  Takayuki Nakashima ,  Shiro Soga ,  Jiro Kajita ,  Jun-ichi Saito ,  Yukimasa Shiotsu ,  Shiro Akinaga

Inventor： Shinji Nara ,  Hiroshi Nakagawa ,  Yutaka Kanda ,  Takayuki Nakashima ,  Shiro Soga ,  Jiro Kajita ,  Jun-ichi Saito ,  Yukimasa Shiotsu ,  Shiro Akinaga

IPC: A61K31/5377 ,  A61K31/12 ,  A61K31/216 ,  A61K31/165 ,  A61K31/44 ,  A61K31/495 ,  A61K31/445 ,  A61K31/40 ,  A61K31/496 ,  A61K31/47 ,  A61K31/5375 ,  A61P35/00

CPC classification number: C07D211/42 ,  A61K31/12 ,  A61K31/165 ,  A61K31/216 ,  A61K31/40 ,  A61K31/4406 ,  A61K31/4409 ,  A61K31/445 ,  A61K31/451 ,  A61K31/495 ,  A61K31/506 ,  A61K31/5375 ,  A61K31/5377 ,  C07C49/84 ,  C07C69/738 ,  C07C205/45 ,  C07C235/78 ,  C07D207/08 ,  C07D207/12 ,  C07D207/27 ,  C07D211/22 ,  C07D211/52 ,  C07D211/54 ,  C07D211/58 ,  C07D211/60 ,  C07D211/62 ,  C07D213/40 ,  C07D213/50 ,  C07D217/06 ,  C07D239/42 ,  C07D241/08 ,  C07D295/088 ,  C07D295/185 ,  C07D307/46 ,  C07D307/52 ,  C07D307/54 ,  C07D317/60 ,  C07D333/22 ,  C07D333/24 ,  C07D409/10

Abstract: The present invention provides Hsp90 family protein inhibitors comprising, as an active ingredient, a benzoyl compound represented by general formula (I): (wherein n represents an integer of 0 to 10; R1 represents substituted or unsubstituted lower alkoxy, substituted or unsubstituted lower alkoxycarbonyl, CONR7R8 or the like; R2 represents substituted or unsubstituted aryl, a substituted or unsubstituted aromatic heterocyclic group or the like; R3 and R5, which may be the same or different, each represent a hydrogen atom, substituted or unsubstituted lower alkyl, substituted or unsubstituted lower alkenyl or the like; and R4 and R6, which may be the same or different, each represent a hydrogen atom, halogen, substituted or unsubstituted lower alkyl, substituted or unsubstituted aryl or the like) or a prodrug thereof, or a pharmaceutically acceptable salt of said benzoyl compound or said prodrug.

Abstract translation: 本发明提供Hsp90家族蛋白质抑制剂，其包含作为活性成分的通式（I）表示的苯甲酰基化合物：（其中n表示0〜10的整数; R 1表示取代或未取代的低级烷氧基，取代或未取代的低级烷氧基羰基 ，CONR7R8等; R2表示取代或未取代的芳基，取代或未取代的芳族杂环基等; R3和R5可相同或不同，分别表示氢原子，取代或未取代的低级烷基，取代或未取代的 未取代的低级烯基等;以及可以相同或不同的R 4和R 6各自表示氢原子，卤素，取代或未取代的低级烷基，取代或未取代的芳基等）或其前药，或药学上 所述苯甲酰化合物或所述前药的可接受的盐。

公开(公告)号：US08952940B2

公开(公告)日：2015-02-10

申请号：US12682089

申请日：2008-10-10

Applicant: Yoshiyuki Nakatani ,  Takayuki Nakashima

Inventor： Yoshiyuki Nakatani ,  Takayuki Nakashima

IPC: G06F3/038 ,  G09G3/36

CPC classification number: G09G3/3622 ,  G09G3/3692

Abstract: A capacity load drive device 1 includes: a logic portion 11 generating a binary logic signal IN; and a driver portion 13 determining, based on a predetermined mode switching signal MODE, whether to generate a binary drive signal or ternary drive signal from the logic signal IN and applying binary or ternary drive signals X1 to Xm generated according to the determination, to an end of a capacity load (liquid crystal cell).

Abstract translation: 容量负载驱动装置1包括：生成二进制逻辑信号IN的逻辑部分11; 以及驱动器部分13，基于预定模式切换信号MODE，确定是否从逻辑信号IN产生二进制驱动信号或三进制驱动信号，并将根据该确定产生的二进制或三进制驱动信号X1至Xm应用于 容量负载的结束（液晶单元）。

公开(公告)号：US20130307435A1

公开(公告)日：2013-11-21

申请号：US13888817

申请日：2013-05-07

Applicant: Shinsuke Takagimoto ,  Takayuki Nakashima ,  Nobuhiro Nishikawa

Inventor： Shinsuke Takagimoto ,  Takayuki Nakashima ,  Nobuhiro Nishikawa

IPC: G05F1/46 ,  H05B33/08

CPC classification number: G05F1/468 ,  H02M1/36 ,  H02M3/1582 ,  H05B33/0815 ,  H05B33/0818 ,  Y02B20/346

Abstract: A power-supply device has a first power supply circuit adapted to generate from an input voltage a first output voltage and a second power supply circuit adapted to generate from the first output voltage a second output voltage. The second power supply circuit monitors the first output voltage to check if it is higher than a first threshold voltage, and also monitors the first power-supply circuit to check if it has started operation for generating the first output voltage, so that the second power supply circuit stays on stand-by, even when the first output voltage is higher than the first threshold voltage, until the first power supply circuit starts operation for generating the first output voltage.

Abstract translation: 电源装置具有适于从输入电压产生第一输出电压的第一电源电路和适于从第一输出电压产生第二输出电压的第二电源电路。 第二电源电路监视第一输出电压以检查其是否高于第一阈值电压，并且还监视第一电源电路以检查其是否已经开始运行以产生第一输出电压，使得第二电源 即使第一输出电压高于第一阈值电压，直到第一电源电路开始运行以产生第一输出电压，供电电路仍然处于待机状态。

公开(公告)号：US07781485B2

公开(公告)日：2010-08-24

申请号：US11718079

申请日：2005-11-09

Applicant: Yushi Kitamura ,  Yutaka Kanda ,  Takayuki Nakashima

Inventor： Yushi Kitamura ,  Yutaka Kanda ,  Takayuki Nakashima

IPC: A61K31/24 ,  A61K31/235

CPC classification number: C07C235/64 ,  C07C69/88 ,  C07C235/60 ,  C07D213/40 ,  C07D295/192

Abstract: The present invention provides Hsp90 family protein inhibitors comprising, as an active ingredient, a benzoic acid derivative represented by General Formula (I): [wherein n represents an integer of 0 to 10; R1 represents substituted or unsubstituted lower alkoxycarbonyl, substituted or unsubstituted aroyl, or the like; R2 represents —NR14R15 (wherein R14 and R15 may be the same or different and each represents a hydrogen atom, substituted or unsubstituted lower alkyl, substituted or unsubstituted aralkyl or the like); R3 and R5 may be the same or different and each represents a hydrogen atom, substituted or unsubstituted lower alkyl or the like; and R4 and R6 may be the same or different and each represents a hydrogen atom, halogen, substituted or unsubstituted lower alkyl or the like] or a prodrug thereof, or a pharmaceutically acceptable salt of said benzoic acid derivative or said prodrug.

Abstract translation: 本发明提供Hsp90家族蛋白抑制剂，其包含通式（I）表示的苯甲酸衍生物作为活性成分：[其中，n表示0〜10的整数， R 1表示取代或未取代的低级烷氧基羰基，取代或未取代的芳酰基等; R2表示-NR14R15（其中R14和R15可以相同或不同，各自表示氢原子，取代或未取代的低级烷基，取代或未取代的芳烷基等）; R 3和R 5可以相同或不同，各自表示氢原子，取代或未取代的低级烷基等; 并且R 4和R 6可以相同或不同，并且各自表示氢原子，卤素，取代或未取代的低级烷基等]或其前药，或所述苯甲酸衍生物或所述前药的药学上可接受的盐。

公开(公告)号：US07767693B2

公开(公告)日：2010-08-03

申请号：US12427847

申请日：2009-04-22

Applicant: Shinji Nara ,  Hiroshi Nakagawa ,  Yutaka Kanda ,  Takayuki Nakashima ,  Shiro Soga ,  Jiro Kajita ,  Jun-ichi Saito ,  Yukimasa Shiotsu ,  Shiro Akinaga

Inventor： Shinji Nara ,  Hiroshi Nakagawa ,  Yutaka Kanda ,  Takayuki Nakashima ,  Shiro Soga ,  Jiro Kajita ,  Jun-ichi Saito ,  Yukimasa Shiotsu ,  Shiro Akinaga

IPC: A01N43/40 ,  C07D211/22 ,  C07C49/303

CPC classification number: C07D211/42 ,  A61K31/12 ,  A61K31/165 ,  A61K31/216 ,  A61K31/40 ,  A61K31/4406 ,  A61K31/4409 ,  A61K31/445 ,  A61K31/451 ,  A61K31/495 ,  A61K31/506 ,  A61K31/5375 ,  A61K31/5377 ,  C07C49/84 ,  C07C69/738 ,  C07C205/45 ,  C07C235/78 ,  C07D207/08 ,  C07D207/12 ,  C07D207/27 ,  C07D211/22 ,  C07D211/52 ,  C07D211/54 ,  C07D211/58 ,  C07D211/60 ,  C07D211/62 ,  C07D213/40 ,  C07D213/50 ,  C07D217/06 ,  C07D239/42 ,  C07D241/08 ,  C07D295/088 ,  C07D295/185 ,  C07D307/46 ,  C07D307/52 ,  C07D307/54 ,  C07D317/60 ,  C07D333/22 ,  C07D333/24 ,  C07D409/10

Abstract: The present invention provides Hsp90 family protein inhibitors comprising, as an active ingredient, a benzoyl compound represented by general formula (I): (wherein n represents an integer of 0 to 10; R1 represents substituted or unsubstituted lower alkoxy, substituted or unsubstituted lower alkoxycarbonyl, CONR7R8 or the like; R2 represents substituted or unsubstituted aryl, a substituted or unsubstituted aromatic heterocyclic group or the like; R3 and R5, which may be the same or different, each represent a hydrogen atom, substituted or unsubstituted lower alkyl, substituted or unsubstituted lower alkenyl or the like; and R4 and R6, which may be the same or different, each represent a hydrogen atom, halogen, substituted or unsubstituted lower alkyl, substituted or unsubstituted aryl or the like) or a prodrug thereof, or a pharmaceutically acceptable salt of said benzoyl compound or said prodrug.

Abstract translation: 本发明提供Hsp90家族蛋白质抑制剂，其包含作为活性成分的通式（I）表示的苯甲酰基化合物：（其中n表示0〜10的整数; R 1表示取代或未取代的低级烷氧基，取代或未取代的低级烷氧基羰基 ，CONR7R8等; R2表示取代或未取代的芳基，取代或未取代的芳族杂环基等; R3和R5可相同或不同，分别表示氢原子，取代或未取代的低级烷基，取代或未取代的 未取代的低级烯基等;以及可以相同或不同的R 4和R 6各自表示氢原子，卤素，取代或未取代的低级烷基，取代或未取代的芳基等）或其前药，或药学上 所述苯甲酰化合物或所述前药的可接受的盐。

公开(公告)号：US07538241B2

公开(公告)日：2009-05-26

申请号：US10584234

申请日：2004-12-24

Applicant: Yushi Kitamura ,  Shinji Nara ,  Hiroshi Nakagawa ,  Rieko Nakatsu ,  Takayuki Nakashima ,  Shiro Soga ,  Jiro Kajita ,  Yukimasa Shiotsu ,  Yutaka Kanda

Inventor： Yushi Kitamura ,  Shinji Nara ,  Hiroshi Nakagawa ,  Rieko Nakatsu ,  Takayuki Nakashima ,  Shiro Soga ,  Jiro Kajita ,  Yukimasa Shiotsu ,  Yutaka Kanda

IPC: C07C225/00 ,  C07C211/00 ,  C07C69/76

CPC classification number: C07C311/21 ,  C07C39/367 ,  C07C43/178 ,  C07C43/21 ,  C07C43/23 ,  C07C49/245 ,  C07C49/248 ,  C07C49/83 ,  C07C59/56 ,  C07C65/105 ,  C07C69/732 ,  C07C69/734 ,  C07C69/736 ,  C07C215/52 ,  C07C217/08 ,  C07C217/76 ,  C07C233/25 ,  C07C233/75 ,  C07C235/06 ,  C07C235/08 ,  C07C235/16 ,  C07C235/34 ,  C07C235/36 ,  C07C235/38 ,  C07C235/42 ,  C07C235/44 ,  C07C235/46 ,  C07C235/80 ,  C07C251/40 ,  C07C251/48 ,  C07C275/32 ,  C07C307/02 ,  C07C309/65 ,  C07C311/08 ,  C07C2601/14 ,  C07D203/10 ,  C07D207/27 ,  C07D211/16 ,  C07D211/58 ,  C07D213/30 ,  C07D213/36 ,  C07D213/40 ,  C07D213/85 ,  C07D217/04 ,  C07D217/06 ,  C07D231/56 ,  C07D235/18 ,  C07D263/32 ,  C07D263/34 ,  C07D271/113 ,  C07D277/24 ,  C07D295/108 ,  C07D295/155 ,  C07D295/185 ,  C07D307/12 ,  C07D307/42 ,  C07D307/52 ,  C07D307/54 ,  C07D307/68 ,  C07D307/91 ,  C07D309/06 ,  C07D317/20 ,  C07D317/54 ,  C07D333/16 ,  C07D405/12

Abstract: (wherein n is an integer of 0 to 10; R1 represents substituted or unsubstituted lower alkyl, substituted or unsubstituted lower alkoxy, substituted or unsubstituted cycloalkyl, substituted or unsubstituted lower alkoxycarbonyl, substituted or unsubstituted heterocyclic-alkyl, substituted or unsubstituted aryl, —CONR7R8, —NR9R10, etc.; R2 represents substituted or unsubstituted aryl or a substituted or unsubstituted heterocyclic group, etc.; R3 and R5 may be the same or different, each represent a hydrogen atom, substituted or unsubstituted lower alkyl, etc.; R4 and R6 may be the same or different, each represent a hydrogen atom, halogen, substituted or unsubstituted lower alkyl, etc.) Provided are an Hsp90 family protein inhibitor comprising, as an active ingredient, a benzene derivative of formula (I) or a prodrug thereof or a pharmaceutically-acceptable salt thereof, etc.

Abstract translation: （其中n为0至10的整数; R 1表示取代或未取代的低级烷基，取代或未取代的低级烷氧基，取代或未取代的环烷基，取代或未取代的低级烷氧基羰基，取代或未取代的杂环 - 烷基，取代或未取代的芳基，-CONR 7 R 8 ，-NR9R10等; R2表示取代或未取代的芳基或取代或未取代的杂环基等; R3和R5可以相同或不同，分别表示氢原子，取代或未取代的低级烷基等; R4 R 6可以相同或不同，各自表示氢原子，卤素，取代或未取代的低级烷基等）。提供一种Hsp90家族蛋白质抑制剂，其包含作为活性成分的式（I）的苯衍生物或 其前药或其药学上可接受的盐等

公开(公告)号：US06724919B1

公开(公告)日：2004-04-20

申请号：US09597263

申请日：2000-06-20

Applicant: Kazuhiro Akiyama ,  Shunichi Mizuhiki ,  Yoshihiro Katayama ,  Takayuki Nakashima ,  Naoya Yamashita ,  Yasuyo Jitsuishi

Inventor： Kazuhiro Akiyama ,  Shunichi Mizuhiki ,  Yoshihiro Katayama ,  Takayuki Nakashima ,  Naoya Yamashita ,  Yasuyo Jitsuishi

IPC: G06K900

CPC classification number: G06F21/32 ,  G06F2221/2149 ,  G07C9/00158

Abstract: According to present invention, there is provide a method of verification for a computer system, the method comprising the steps of acquiring a face image of a user at any time of a user operation, verifying whether the acquired face image coincides with any one of pre-registered face images, and executing a preset process where the acquired face image coincides with the any one of the pre-registered face images.

Abstract translation: 根据本发明，提供了一种用于计算机系统的验证方法，所述方法包括以下步骤：在用户操作的任何时间获取用户的脸部图像，验证所获取的脸部图像是否与预 并且执行预先设定的处理，其中获取的脸部图像与预先登记的面部图像中的任何一个一致。

公开(公告)号：US20100259513A1

公开(公告)日：2010-10-14

申请号：US12682089

申请日：2008-10-10

Applicant: Yoshiyuki Nakatani ,  Takayuki Nakashima

Inventor： Yoshiyuki Nakatani ,  Takayuki Nakashima

IPC: G06F3/038 ,  H03B1/00

CPC classification number: G09G3/3622 ,  G09G3/3692

Abstract: A capacity load drive device 1 includes: a logic portion 11 generating a binary logic signal IN; and a driver portion 13 determining, based on a predetermined mode switching signal MODE, whether to generate a binary drive signal or ternary drive signal from the logic signal IN and applying binary or ternary drive signals X1 to Xm generated according to the determination, to an end of a capacity load (liquid crystal cell).

Abstract translation: 容量负载驱动装置1包括：生成二进制逻辑信号IN的逻辑部分11; 以及驱动器部分13，基于预定模式切换信号MODE，确定是否从逻辑信号IN产生二进制驱动信号或三进制驱动信号，并将根据该确定产生的二进制或三进制驱动信号X1至Xm应用于 容量负载的结束（液晶单元）。

公开(公告)号：US07776849B2

公开(公告)日：2010-08-17

申请号：US11917239

申请日：2006-06-29

Applicant: Shinpei Yamaguchi ,  Takayuki Nakashima ,  Yutaka Kanda

Inventor： Shinpei Yamaguchi ,  Takayuki Nakashima ,  Yutaka Kanda

IPC: A61K31/395 ,  C07D225/06 ,  A61P35/00

CPC classification number: C07D225/06 ,  C07F7/1804

Abstract: The present invention provides a benzenoid ansamycin derivative represented by Formula (I) (wherein R1 and R2 each represent a hydrogen atom or are combined together to form a bond, R8 represents a bond or an oxygen atom, R11 represents hydroxy, substituted or unsubstituted lower alkoxy or substituted or unsubstituted lower alkanoyloxy, R15 represents a hydrogen atom or methoxy, R22 represents a hydrogen atom, substituted or unsubstituted lower alkyl, substituted or unsubstituted lower alkanoyl or substituted or unsubstituted aroyl, R4 and R5 each represent a hydrogen atom or are combined together to form a bond, R18 represents a hydrogen atom, or the like, R21 represents hydroxy or the like, and R17 and R19 may be the same or different and each represents a hydrogen atom, or the like) or a pharmaceutically acceptable salt thereof.

Abstract translation: 本发明提供由式（I）表示的苯并安莎霉素衍生物（其中R1和R2各自表示氢原子或组合在一起形成键，R8表示键或氧原子，R11表示羟基，取代或未取代的低级 烷氧基或取代或未取代的低级烷酰氧基，R 15表示氢原子或甲氧基，R 22表示氢原子，取代或未取代的低级烷基，取代或未取代的低级烷酰基或取代或未取代的芳酰基，R4和R5各自表示氢原子或被结合 一起形成键，R 18表示氢原子等，R 21表示羟基等，R 17和R 19可以相同或不同，各自表示氢原子等）或其药学上可接受的盐 。